1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study)

BACKGROUND: Baloxavir marboxil (BXM), a selective cap-dependent endonuclease inhibitor, has demonstrated efficacy + safety for influenza in otherwise healthy patients. We present subgroup analyses for (i) United States vs. Japan (J), (ii) time (t) of treatment (early: ≥0 to ≤24 hours, vs. late: >...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Keiko, Portsmouth, Simon, Shishido, Takao, Uehara, Takeki, Hayden, Frederick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252458/
http://dx.doi.org/10.1093/ofid/ofy209.115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252458/
http://dx.doi.org/10.1093/ofid/ofy209.115

Ejemplares similares